IP Library Granted Patent US 10,668,160
Granted Patent B2
US 10,668,160 · App. 13/335,780 · Granted Jun 2, 2020

DPI formulation containing sulfoalkyl ether cyclodextrin

Inventors: James D. Pipkin (Lawrence, KS); Gerold L. Mosher (Kansas City, MO); Douglas B. Hecker (Liberty, MO)
Assignee: CyDex Pharmaceuticals, Inc.
A61K47/40A61K9/0075Y10T428/2982
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,668,160
App. No.
13/335,780
Granted
Jun 2, 2020
Kind
B2
Abstract

An inhalable dry powder formulation containing SAE-CD and an active agent is provided. The formulation is adapted for administration by DPI. The SAE-CD serves as a carrier rather than as an absorption enhancer. The average particle size of the SAE-CD is large enough to preclude (for the most part) pulmonary deposition thereof. Following release from the DPI device, the SAE-CD-containing particles dissociate from the active agent-containing particles in the buccal cavity or throat, after which the active agent-containing particles continue deeper into the respiratory tract. The physicochemical and morphological properties of the SAE-CD are easily modified to permit optimization of active agent and carrier interactions. Drugs having a positive, neutral or negative electrostatic charge can be delivered by DPI when SAE-CD is used as a carrier.

Claims (23)

1. A composition comprising agglomerated particles comprising sulfoalkyl ether cyclodextrin, wherein the composition comprises less than 10% by weight moisture and has a property of a bulk density of 0.34 g/cc to 0.55 g/cc, a CARR's index of about 10% to about 40%, a median particle diameter of about 10 microns to about 300 microns, and wherein the agglomerated particles have a rough surface.

2. The composition of claim 1 , wherein the sulfoalkyl ether cyclodextrin is a compound, or a mixture of compounds, of the Formula 1:

wherein:

n is 4, 5, or 6;

R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , and R 9 are each, independently, O − or a O—(C 2-6 alkylene)-SO 3 − group, wherein at least one of R 1 to R 9 is independently a O—(C 2 -C 6 alkylene)-SO 3 − group; and

S 1 , S 2 , S 3 , S 4 , S 5 , S 6 , S 7 , S 8 , and S 9 , are each, independently, a pharmaceutically acceptable cation selected from the group consisting of H + , alkali metals, alkaline earth metals, ammonium ions and amine cations.

3. The composition of claim 1 , wherein the composition comprises particles with a median particle diameter of about 175 microns to about 277 microns.

4. The composition of claim 1 , wherein the composition comprises particles with a median particle diameter of about 37 microns to about 125 microns.

5. The composition of claim 1 , wherein the composition comprises a particle size distribution span of about 1.5 to about 2.9.

6. The composition of claim 1 , wherein the composition comprises a moisture content of less than 8% by weight.

7. The composition of claim 1 , wherein the composition comprises a moisture content of less than 2.5% by weight.

8. The composition of claim 1 , wherein the composition comprises a moisture content of less than 1% by weight.

9. The composition of claim 1 , wherein the composition further comprises an excipient selected from the group consisting of an antioxidant, acidifying agent, alkalizing agent, buffering agent, solubility-enhancing agent, penetration enhancer, electrolyte, fragrance, glucose, glidant, stabilizer, bulking agent, cryoprotectant, plasticizer, flavor, sweetener, surface tension modifier, density modifier, volatility modifier, hydrophilic polymer, water soluble polymer, and combinations thereof.

10. The composition of claim 1 , wherein the composition comprises a moisture content of 3.17-5.19% by weight.

11. The composition of claim 1 prepared by a process comprising a spray agglomeration of a feed solution using a spray drier apparatus to form agglomerated particles.

12. The composition of claim 11 , wherein the spray drier apparatus comprises a pressure nozzle; an inlet; an outlet; a fluid bed inlet; and a fluid product bed.

13. The composition of claim 1 , prepared by a process comprising:

(a) providing a liquid feed comprising a liquid carrier and SAE-CD;

(b) forming a fluidized bed of particles comprising SAE-CD in a drying chamber of a fluidized bed spray dryer apparatus;

(c) removing fine particles from the fluidized bed and returning them back into the drying chamber;

(d) atomizing liquid feed into the drying chamber: conducting larger particles to a second chamber containing a fluidized bed of particles; and

(f) collecting particulate composition to provide the composition comprising SAE-CD.

14. The composition of claim 13 , wherein the process further comprises removing fine particles from the second chamber and returning them to the drying chamber.

Assignments (4)
SECURITY INTEREST Recorded Oct 18, 2023
From: CYDEX PHARMACEUTICALS, INC.; LIGAND PHARMACEUTICALS INCORPORATED; METABASIS THERAPEUTICS, INC.; PFENEX INC.
To: CITIBANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 065271/0025 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2022
From: PIPKIN, JAMES D.
To: CYDEX, INC.
Reel/Frame 061337/0713 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2022
From: MOSHER, GEROLD L.; HECKER, DOUGLAS B.
To: CYDEX PHARMACEUTICALS, INC.
Reel/Frame 061337/0797 →
CHANGE OF NAME Recorded Oct 6, 2022
From: CYDEX, INC.
To: CYDEX PHARMACEUTICALS, INC.
Reel/Frame 061621/0152 →